6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。

智通财经06-15

6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗PF-07275315为抗IL-4/IL-13/TSLP三抗这两款产品目前在国际范围内均处于2期临床阶段。根据辉瑞公开资料介绍PF-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2443939986?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-15 10:55","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2443939986","market":"us","top_or_hot":-1,"title":"6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。","media":"智通财经","content":"<div>\n<p>6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗PF-07275315为抗IL-4/IL-13/TSLP三抗这两款产品目前在国际范围内均处于2期临床阶段。根据辉瑞公开资料介绍PF-...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-15 10:55 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗PF-07275315为抗IL-4/IL-13/TSLP三抗这两款产品目前在国际范围内均处于2期临床阶段。根据辉瑞公开资料介绍PF-...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDE","symbol_name":"科尔黛伦矿业","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2443939986","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443939986","pubTimestamp":1718420112,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CDE":"科尔黛伦矿业","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4592":"伊斯兰概念","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999001176.USD":"United Global Healthcare Acc USD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4017":"黄金","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4550":"红杉资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","TSLP":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4581":"高盛持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","PFE":"辉瑞","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"translate_title":"On June 13, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Pfizer's two new Class 1 drugs have been approved clinically, both of which are planned to be developed to treat moderate to severe atopic dermatitis in adults. According to Pfizer's public information, both products are trispecific antibodies, which are new molecular entities in the company's inflammatory and immune pipelines.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLP":1,"PFE":1,"CDE":1},"content_text":"6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗PF-07275315为抗IL-4/IL-13/TSLP三抗这两款产品目前在国际范围内均处于2期临床阶段。根据辉瑞公开资料介绍PF-07264660和PF-07275315这两款三特异性抗体在更有效阻断IL-4/IL-13信号通路的同时可以通过抑制TSLP产生更广泛的效果或者通过抑制IL-33通路进一步抑制瘙痒有望对治疗特应性皮炎产生更好的疗效。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443939986"}